Efficacy and safety of Vibegron for the treatment of residual overactive bladder symptoms after laser vaporization of the prostate: A single‐center prospective randomized controlled trial ( VAPOR TRIAL )
LUTS: Lower Urinary Tract Symptoms · 2024
DOI: 10.1111/luts.12529 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift LUTS: Lower Urinary Tract Symptoms, 2024. Verfasst von Narihito Seki und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, Japan. Hauptthemen laut MEDLINE: Urinary Bladder, Overactive, Laser Therapy. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kyorin Pharmaceutical.
Abstract (Originalsprache)
Objectives
This study aimed to evaluate the efficacy and safety of Vibegron for the treatment of residual overactive bladder (OAB) symptoms after laser vaporization of the prostate (photo‐selective vaporization of the prostate, contact laser vaporization of the prostate, and thulium laser vaporization).
Methods
This randomized, open‐label, parallel‐group, single‐center superiority trial with a 12‐week observation (jRCTs071190040) enrolled male patients with OAB aged 40 years or older who had undergone laser vaporization of the prostate for not less than 12 weeks and not more than 1 year earlier. Patients were allocated to receive Vibegron 50 mg once daily or follow‐up without treatment for 12 weeks.
Results
Forty‐seven patients were enrolled between January 2020 and March 2023. The median age (interquartile range) was 75.5 (72.5–78.5) years for the Vibegron group and 76.5 (71.0–81.0) years for the control group. The intergroup difference in the mean change (95% confidence interval) in the 24‐hour urinary frequency at 12 weeks after randomization was −3.66 (−4.99, −2.33), with a significant decrease for the Vibegron group. The Overactive Bladder Symptom Score, International Prostate Symptom Score, IPSS storage score, and Overactive Bladder Questionnaire score significantly improved for the Vibegron group. Voided volume per micturition also increased for the Vibegron group.
Conclusions
The administration of 50 mg of Vibegron once daily for 12 weeks showed significant improvement compared with follow‐up without treatment in bladder storage (OAB) symptoms after laser vaporization of the prostate for symptomatic benign prostatic hyperplasia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, Japan.
- Medical Affairs, Kyorin Pharmaceutical Co, Ltd, Tokyo, Japan.
ORCID-Profile: Narihito Seki, Takashi Dejima, Shotaro Maeda
Förderung
- Kyorin Pharmaceutical
Zitieren
APA
Seki, N., Masaoka, H., Song, Y., Dejima, T., Sato, Y., & Maeda, S. (2024). Efficacy and safety of Vibegron for the treatment of residual overactive bladder symptoms after laser vaporization of the prostate: A single‐center prospective randomized controlled trial ( VAPOR TRIAL ). LUTS: Lower Urinary Tract Symptoms. https://doi.org/10.1111/luts.12529
Vancouver
Seki N, Masaoka H, Song Y, Dejima T, Sato Y, Maeda S. Efficacy and safety of Vibegron for the treatment of residual overactive bladder symptoms after laser vaporization of the prostate: A single‐center prospective randomized controlled trial ( VAPOR TRIAL ). LUTS: Lower Urinary Tract Symptoms. 2024. doi:10.1111/luts.12529
BibTeX
@article{Seki2024,
author = {Seki, Narihito and Masaoka, Hiroyuki and Song, Yoohyun and Dejima, Takashi and Sato, Yoshiaki and Maeda, Shotaro},
title = {Efficacy and safety of Vibegron for the treatment of residual overactive bladder symptoms after laser vaporization of the prostate: A single‐center prospective randomized controlled trial ( VAPOR TRIAL )},
journal = {LUTS: Lower Urinary Tract Symptoms},
year = {2024},
doi = {10.1111/luts.12529}
}
EUVIMED